Zydus’ ZyCoV-D Receives the DCGI’s EUA for the Treatment of COVID-19

 Zydus’ ZyCoV-D Receives the DCGI’s EUA for the Treatment of COVID-19

Shots:

  • The DCGI has granted a EUA for ZyCoV-D which is the world’s first plasmid DNA vaccine for COVID-19. The company is planning to seek approval for the two-dose regimen of the vaccine
  • ZyCoV-D will become India’s first vaccine for adolescents aged 12-18 yrs. The vaccine is safe and well-tolerated
  • ZyCoV-D is a three-dose, needle-free, intradermal vaccine that leads to a reduction in any side effects & administered using PharmaJet for painless delivery. The company plans to manufacture 10-12 crore doses annually

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Zydus

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post